Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy

Exclusion Criteria

• •6. \- Ability to provide informed consent before any trial-related activities
• •7. \- Access to a telephone
• •* The cause of the CKD does not need to be due specifically to diabetes
• •1. \- Active malignancy
• •2. \- History of pancreatitis
• •3. \- Active substance abuse
• •4. \- Severe COPD
• •5. \- Pulmonary fibrosis
• •6. \- Symptomatic angina or recent myocardial infarction within 6 months
• •7. \- Severe peripheral vascular disease
• •8. \- Cirrhosis
• •9. \- New York Health Association (NYHA) Class III-IV congestive heart failure
• •10. \- Severe cognitive impairment
• •11. \- Drug addiction
• •12. \- History of non-adherence to therapy
• •13. \- Active infection
• •14. \- Expected life expectancy \< 5 years
• •15. \- Type 1 diabetes mellitus
• •16. \- History of diabetic ketoacidosis within the last 12 months
• •17. \- Planning on undergoing bariatric surgery in next 9 months.
• •18. \- Pregnant, breast-feeding, or planned pregnancy prior to the end of participation or not using adequate contraceptive measures
• •19. \- Self-reported average consumption of \> 21 alcoholic beverages per week or binge drinking
• •20. \- Psychiatric hospitalization in past year
• •21. \- Principal investigator discretion (i.e. concerns about safety, compliance)
• •22. \- Known or suspected allergy to trial medication
• •23. \- Previous participation (i.e. randomized) in this trial
• •24. \- Use of GLP1-RA or pramlintide within 90 days prior to screening
• •25. \- Use of metformin (contraindicated with eGFR \< 30 ml/min/1.73m2)
• •26. \- Use of DPP-4 inhibitors within 30 days prior to screening
• •27. \- Personal or family history of medullary thyroid cancer, multiple endocrine neoplasia types 2A and 2B syndrome
• •28. \- Last hemoglobin A1c ≥ 12% or A1c \<6% (to avoid risk of hypoglycemia) prior to screening